Jacob Coxon, who spent three years at OpenAI and Anthropic, said he is leaving the industry because no lab can responsibly build superhuman AI without government intervention or a coordinated slowdown.
Jacob Coxon, who spent three years at OpenAI and Anthropic, said he is leaving the industry because no lab can responsibly build superhuman AI without government intervention or a coordinated slowdown.

A 27-year-old Anthropic researcher who helped train frontier models has quit the AI industry, warning that competition between labs is pushing development toward self-improving systems that could become uncontrollable by 2027.
"Companies are effectively gambling with our lives," Jacob Coxon said in announcing his resignation Sept. 8, according to the Wall Street Journal.
Coxon spent part of the past three years on pre-training research at OpenAI before joining Anthropic earlier this year, drawn by its safety-focused reputation. He said he no longer believes either organization is moving cautiously enough toward systems capable of improving their own capabilities faster than humans can understand or control them.
His exit lands at a sensitive moment for Anthropic, which is preparing for an initial public offering and has built its brand around responsible AI development. A top internal researcher publicly questioning the company's safety bottom line could sharpen regulatory scrutiny and prompt investors to reassess how the lab balances safety commitments against the pace of model releases.
The resignation adds to a list of senior AI figures who have left leading labs while warning about the balance between commercial progress and safety. Coxon's specific concern is a future generation of systems that could improve themselves — a capability he argues is being pursued faster than the safeguards needed to control it. He said he expects the situation could already be out of control by the end of next year, and that people building AI sincerely believe the technology could kill all humans within a decade.
Anthropic was founded by former OpenAI employees and has positioned its Claude models around responsible development, a contrast it has used to separate itself from the more commercially driven OpenAI. Coxon's criticism cuts at that identity: even a lab that takes safety seriously may feel compelled to keep advancing because rivals are doing the same. If one company slows down, another moves faster.
That dynamic extends beyond the US. Coxon pointed to competition with innovative Chinese firms as a force making safety compromises inevitable. Chinese labs have narrowed the cost and capability gap in frontier model development, intensifying pressure on US companies to ship new systems quickly rather than pause for additional safeguards. The result is a growing argument inside the industry over whether AI development is moving faster than the systems built to monitor and govern it.
For Anthropic, the timing is awkward. The company is advancing toward a public listing, and its valuation rests partly on a safety-first brand that distinguishes it from OpenAI. A departing researcher questioning that foundation could invite closer scrutiny from regulators and complicate the story the company takes to public markets.
Coxon's answer is not for individual labs to promise more caution. He argues the industry needs rules and coordination that apply across companies and countries — government intervention or a coordinated slowdown. Without it, he said, no company can responsibly develop systems that outperform humans across a broad range of tasks.
Whether AI is genuinely close to becoming uncontrollable remains a matter of debate. Coxon's warning reflects his assessment of where development could lead, not an established prediction. But it joins a broader argument over whether models are being deployed with enough oversight as they take on longer sequences of tasks with less human intervention. For investors weighing AI exposure, the episode highlights a risk that is difficult to price: the possibility that the race itself becomes the problem.
This article is for informational purposes only and does not constitute investment advice.